Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Rhythm Pharmaceuticals' lone approved product currently generates minimal sales. If you're interested in capitalizing on the ...

India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...

It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...